Next Generation Stool-based DNA Technology Study Results of 92% for Colorectal Cancer Detection  Healthtorial

Next Generation Stool-based DNA Technology Study Results of 92% for Colorectal Cancer Detection Healthtorial

Next Generation Stool-based DNA Technology Study Results of 92% for Colorectal Cancer Detection

EXACT Sciences Corporation today announced the published results of a study in which stool and blood plasma were assessed, in a head-to-head comparison, for the detection of colorectal cancer (CRC). Using an improved BEAMing DNA detection technology from Johns Hopkins University, study results demonstrated 92 percent sensitivity for detecting CRC in stool samples. Importantly, results showed that, using this BEAMing technology, stool-based DNA testing outperformed blood plasma testing, especially for the detection of early stage CRCs. EXACT Sciences has exclusive rights to the Johns Hopkins University BEAMing technology for use in a next generation stool-based DNA (sDNA) detection technology for CRC.

In the study, a total of 25 stool DNA samples from colorectal cancer patients were analyzed and a next generation sDNA technology correctly identified 23 (92%) of the cancers. In the 16 of 25 cases where there were paired stool and plasma DNA samples, the sDNA technology detected mutated DNA in stool in 14 cases (88%) while only 8 (50%) corresponding plasma DNA samples had detectable levels of mutated DNA. Further, when late-stage disease (Stage IV) is removed from the total, non-invasive sDNA performance remained at 86% (12/14) while plasma DNA performance fell to 43% (6/14). The results of the study, Analysis of Mutations in DNA Isolated from Plasma and Stool of Colorectal Cancer Patients, were published in the August journal of Gastroenterology.

“We are very excited by these latest results as they underscore the early detection power that is achievable when combining advanced detection techniques with a DNA target-rich environment like stool,” commented Jeffrey R. Luber, EXACT Sciences’ President and Chief Executive Officer. “Although this technology is still at the very early stages of development, the results of this latest study suggest that stool, which is in immediate contact with the colorectal cancers and polyps, is the more reliable and robust source of mutated DNA when compared to blood plasma for detecting early stage colorectal cancer—an essential characteristic for a mass screening test.”

Categories: Bio Technology, Disease, Health, Life Science, Medical, Safety

Tags: BEAMing, blood, colorectal cancer, CRC, DNA, exact sciences, jeffrey luber, johns hopkins university, journal of Gastroenterology, plasma, research reports, stool, study, technology

You can use these XHTML tags

« Luminaries Call For Ending AIDS through a Vaccine

Investors Led by The Frost Group Agree to Make $15 Million Investment in OPKO Health »

Investors Led by The Frost Group Agree to Make $15 Million Investment in OPKO Health

Next Generation Stool-based DNA Technology Study Results of 92% for Colorectal Cancer Detection

Luminaries Call For Ending AIDS through a Vaccine

Food Safety Monitoring for the Beijing Games

Major Health Organizations in China Install Defibrillators

EcoNugenics Develops Safe Antidote for Lead Toxicity in Children

CDC Numbers: HIV Prevention in US a Failure

tobaccoStep Out of the KitchenXclair Reported to Be Safe and Effective in Study Published in European Journal of DermatologyHealthy Food in WattsMaking it Easier to be Healthy100-Year-Olds are Still HipSeven Million Lives with the Passing of AIDS BillLabor Agency and Migrant Education Program Partner to Prevent Heat Illness in Agricultural IndustryAlmost 50% of Americans Exposed to Second-Hand SmokeHollywoods War on Smoking ContinuesFood Safety Monitoring for the Beijing Games

ads
ads

Weight Loss